Thermo Fisher Scientific Inc. · NYSE (us_market)
Healthcare · Diagnostics & Research · United States
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-02-06$572.71 RISE2025-06-17$390.26 PEAK2025-08-22$499.99 197d | -31.9% 131d | Missed | Missed | — | — | +28.1% 66d | Missed |
DROP2024-09-10$624.21 RISE2024-11-18$501.29 PEAK2025-01-30$606.74 142d | -19.7% 69d | Missed | Missed | — | — | +21.0% 73d | Missed |
DROP2023-07-26$574.41 RISE2023-10-27$431.41 PEAK2024-01-22$553.39 180d | -24.9% 93d | Missed | Missed | — | — | +28.3% 87d | Missed |
DROP2022-08-15$604.49 RISE2022-11-09$484.71 PEAK2023-01-23$604.82 161d | -19.8% 86d | Missed | Missed | — | — | +24.8% 75d | Missed |
DROP2022-04-07$612.21 RISE2022-06-17$500.90 PEAK2022-08-15$604.49 130d | -18.2% 71d | Missed | Missed | — | — | +20.7% 59d | Missed |
DROP2021-12-31$667.24 RISE2022-03-08$524.00 PEAK2022-04-07$612.21 97d | -21.5% 67d | Missed | Missed | — | — | +16.8% 30d | Missed |
DROP2020-11-06$527.66 RISE2020-11-24$439.56 PEAK2021-01-25$518.83 80d | -16.7% 18d | Missed | Missed | — | — | +18.0% 62d | Missed |
DROP2020-01-22$340.05 RISE2020-03-23$255.30 PEAK2020-06-05$354.20 135d | -24.9% 61d | Missed | Missed | — | — | +38.7% 74d | Missed |
Despite Thermo Fisher Scientific's underperformance relative to the SPX over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Thermo Fisher (TMO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
QIAGEN cuts its 2026 growth outlook after a Q1 miss, but margins, cash flow and a debt-free balance sheet could steady the narrative.
QGEN targets steadier growth through 2027, leaning on new launches, Connect automation and QIAstat-Dx menu expansion amid choppy demand.
We recently compiled a list of the 10 Most Widely Held Stocks by Individuals in 2026. Thermo Fisher Scientific Inc. (NYSE:TMO) is among the most widely held stocks by individuals. TheFly reported on May 14 that RBC Capital restarted coverage of TMO with a Sector Perform rating and assigned a $490 price objective. The firm pointed […]
Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the best medical technology stocks to buy right now. On May 20, Thermo Fisher Scientific Inc. (NYSE:TMO) hosted its annual Investor Day in New York City, where CEO Marc N. Casper and the senior leadership team outlined the company’s long-term financial targets and strategic priorities. A key […]
2026-05-26. The following slide deck was published by Thermo Fisher Scientific Inc.
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Bioprocess Automation Software Market size & share revenue was valued at approximately USD 1.67 Billion in 2025 and is expected to reach USD 1.90 Billion in 2026 and is expected to reach around USD 6.19 Billion by 2035, at a CAGR of 14 between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Xeris Pharmaceuticals
Thermo Fisher Scientific Inc. (TMO) Analyst/Investor Day May 20, 2026 9:00 AM EDTCompany ParticipantsRafael Tejada - Vice President of Investor...
Thermo Fisher Scientific recently opened a new bioanalytical and biomarker laboratory in Gothenburg, Sweden, enhancing its GLP-capable support for global drug development and expanding its PPD™ Laboratory Services network alongside existing sites in the US and China. This expansion underlines Thermo Fisher’s push to be a deeper end-to-end partner for pharma and biotech customers, particularly in complex modalities such as cell and gene therapies. We’ll now examine how this expanded...
Thermo Fisher Scientific recently opened a new bioanalytical and biomarker laboratory in Gothenburg, Sweden, enhancing its GLP-capable support for global drug development and expanding its PPD™ Laboratory Services network alongside existing sites in the US and China. This expansion underlines Thermo Fisher’s push to be a deeper end-to-end partner for pharma and biotech customers, particularly in complex modalities such as cell and gene therapies. We’ll now examine how this expanded...
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Genome Editing Market size & share revenue was valued at approximately USD 11.2 Billion in 2025 and is expected to reach USD 13.1 Billion in 2026 and is expected to reach around USD 55.7 Billion by 2035, at a CAGR of 17.4% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Genome Medical Inc., Editas Medici
WALTHAM, Mass., May 20, 2026--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.47 per common share, payable on July 15, 2026, to shareholders of record as of June 15, 2026.
Generation IM Q1 2026 13F: portfolio drops to $11.16B; top holdings MSFT, AMZN & GOOGL; big buys/sells and new picks.
Tom Hancock, GMO US Quality ETF portfolio manager, joins 'The Exchange' to discuss Nvidia's upcoming earnings results, a potential turning point in price cycles and much more.
WALTHAM, Mass., May 20, 2026--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, hosted its Investor Day today. Chairman and Chief Executive Officer Marc N. Casper and members of the senior leadership team highlighted the company’s industry leadership and the essential role of its best-in-class products and services to customers around the world.
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| TMO | +4.97% | -3.16% | -15.00% | +22.27% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +2.00% | +2.56% | -11.56% | +9.58% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 16.73M | $8.23B | 0.28% | Added+0.7% | 2026-03-31 |
| FidelityFMR | fundamental | 10.78M | $5.30B | 0.28% | Added+10.0% | 2026-03-31 |
| CapResearch | fundamental | 4.41M | $2.17B | 0.34% | Added+51.5% | 2026-03-31 |
| Viking | long/short | 1.67M | $819.88M | 2.29% | Added+110.3% | 2026-03-31 |
| Wellington | fundamental | 1.48M | $726.60M | 0.14% | Trimmed-57.4% | 2026-03-31 |
| Citadel | multi-strat | 353.5K | $173.78M | 0.22% | Trimmed-19.1% | 2026-03-31 |
| DEShaw | quant | 302.8K | $148.86M | 0.09% | Added+537.0% | 2026-03-31 |
| TwoSigma | quant | 187.9K | $92.36M | 0.07% | Added+1920.4% | 2026-03-31 |
| RenTech | quant | 139.0K | $68.30M | 0.11% | New | 2026-03-31 |
| Bridgewater | macro | 14.5K | $7.12M | 0.03% | Added+759.3% | 2026-03-31 |
| TRowePrice | fundamental | 6.32M | $3.10M | 0.36% | Trimmed-18.0% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-22 | Chai Nelson | Director | A Grant / award | 499 | — | +$0 |
| 2026-05-22 | CHANDY RUBY R | Director | A Grant / award | 499 | — | +$0 |
| 2026-05-22 | HARRIS C MARTIN | Director | A Grant / award | 499 | — | +$0 |
| 2026-05-22 | Jacks Tyler | Director | A Grant / award | 499 | — | +$0 |
| 2026-05-22 | JOHNSON JENNIFER M | Director | A Grant / award | 499 | — | +$0 |
| 2026-05-22 | Keith R. Alexandra | Director | A Grant / award | 499 | — | +$0 |
| 2026-05-22 | Lynch Karen S | Director | A Grant / award | 499 | — | +$0 |
| 2026-05-22 | Spar Debora L | Director | A Grant / award | 499 | — | +$0 |
| 2026-05-22 | SPERLING SCOTT M | Director | A Grant / award | 499 | — | +$0 |
| 2026-05-22 | WEISLER DION J | Director | A Grant / award | 499 | — | +$0 |
| 2026-05-22 | WEISLER DION J | Director | F Tax withholding | 80 | $451.79 | −$36.3K |
| 2026-04-29 | Pettiti Gianluca | President & COO | S Open-market sale | 400 | $462.66 | −$185.1K |
| 2026-03-31 | WEISLER DION J | Director | A Grant / award(deriv) | 79 | — | — |
| 2026-03-31 | JOHNSON JENNIFER M | Director | A Grant / award(deriv) | 66 | — | — |
| 2026-03-31 | Lynch Karen S | Director | A Grant / award(deriv) | 66 | — | — |
| 2026-03-31 | Keith R. Alexandra | Director | A Grant / award(deriv) | 66 | — | — |
| 2026-03-31 | SPERLING SCOTT M | Director | A Grant / award(deriv) | 90 | — | — |
| 2026-03-12 | Shafer Michael D | Executive Vice President | S Open-market sale | 1,607 | $499.40 | −$802.5K |
| 2026-03-09 | CASPER MARC N | Chairman & CEO | M Option exercise(deriv) | 4,000 | — | +$0 |
| 2026-03-09 | CASPER MARC N | Chairman & CEO | S Open-market sale | 264 | $519.74 | −$137.2K |
| 2026-03-09 | CASPER MARC N | Chairman & CEO | S Open-market sale | 516 | $519.13 | −$267.9K |
| 2026-03-09 | CASPER MARC N | Chairman & CEO | S Open-market sale | 106 | $517.83 | −$54.9K |
| 2026-03-09 | CASPER MARC N | Chairman & CEO | S Open-market sale | 201 | $516.73 | −$103.9K |
| 2026-03-09 | CASPER MARC N | Chairman & CEO | S Open-market sale | 348 | $515.64 | −$179.4K |
| 2026-03-09 | CASPER MARC N | Chairman & CEO | S Open-market sale | 570 | $514.71 | −$293.4K |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-07-22upcoming | 5.72 | — | — |
| 2026-04-23 | 5.24 | 5.44 | +3.79% |
| 2026-01-29 | 6.45 | 6.57 | +1.87% |
| 2025-10-22 | 5.50 | 5.79 | +5.32% |
| 2025-07-23 | 5.23 | 5.36 | +2.55% |
| 2025-04-23 | 5.10 | 5.15 | +0.94% |
| 2025-01-30 | 5.94 | 6.10 | +2.66% |
| 2024-10-23 | 5.25 | 5.28 | +0.50% |
| 2024-07-24 | 5.13 | 5.37 | +4.72% |
| 2024-04-24 | 4.71 | 5.11 | +8.45% |
| 2024-01-31 | 5.65 | 5.67 | +0.42% |
| 2023-10-25 | 5.61 | 5.69 | +1.37% |
| 2023-07-26 | 5.43 | 5.15 | -5.17% |
| 2023-04-26 | 5.03 | 5.03 | -0.08% |
| 2023-02-01 | 5.20 | 5.40 | +3.84% |
| 2022-10-26 | 4.82 | 5.08 | +5.50% |